EO2401 MICROBIOME DERIVED THERAPEUTIC VACCINE plus NIVOLUMAB, WITH/WITHOUT STANDARD CONTINUOUS, OR LOW-DOSE SYMPTOM DIRECTED, BEVACIZUMAB, IN RECURRENT GLIOBLASTOMA: PHASE 1-2 EOGBM1-18/ROSALIE STUDY

被引：2

作者：

Reardon, David ^{[1
]}

Idbaih, Ahmed ^{[2
]}

Vieito, Maria ^{[3
]}

Tabatabai, Ghazaleh ^{[4
]}

Stradella, Agostina ^{[5
]}

Ghiringhelli, Francois ^{[6
]}

Burger, Michael ^{[7
]}

Mildenberger, Iris ^{[8
]}

Herrlinger, Ulrich ^{[4
]}

Gonzalez, Macarena ^{[3
]}

GilMartin, Marta ^{[5
]}

Renovanz, Mirjam ^{[4
]}

Touat, Mehdi ^{[9
]}

Wen, Patrick ^{[1
]}

Wick, Antje ^{[4
]}

Gouttefangeas, Cecile ^{[10
]}

Maia, Ana ^{[10
]}

Bonny, Chistophe ^{[11
]}

Fagerberg, Jan ^{[11
]}

Wick, Wolfgang ^{[12
,13
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Sorbonne Univ, Hop Univ Pitie Salpetriere, AP HP, ICM, Paris, MA, France

[3] Hosp Univ Vall Hebron, Barcelona, Spain

[4] Univ Klinikum, Tubingen, Germany

[5] Inst Catala Oncol, Hosp Duran & Reynals, Barcelona, Spain

[6] Ctr Georges Francois Leclerc, Dijon, France

[7] Univ Klinikum Frankfurt Goethe Univ, Frankfurt, Germany

[8] Med Fak, Mannheim, Germany

[9] Hop Univ Pitie Salpetriere, Paris, France

[10] Eberhard Karls Univ Tubingen, Dept Immunol, Tubingen, Germany

[11] Enterome, Paris, France

[12] Univ Klinikum Heidelberg, Heidelberg, Germany

[13] German Canc Res Ctr, Heidelberg, Germany

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0642

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

642

引用

页码：A673 / A673

页数：1

共 3 条

[1] STRONG IMMUNE RESPONSE TO THERAPEUTIC VACCINATION WITH EO2401 MICROBIOME DERIVED THERAPEUTIC VACCINE plus NIVOLUMAB: INTERIM REPORT OF THE EOGBM1-18/ROSALIE STUDY
Maia, Ana
Toussaint, Helene
Magalhaes, Joao Gamelas
Reardon, David
Idbaih, Ahmed
Vieito, Maria
Tabatabai, Ghazaleh
Stradella, Agostina
Ghiringhelli, Francois
Burger, Michael C.
Mildenberger, Iris
Herrlinger, Ulrich
Gonzalez, Macarena
Hervieu, Alice
GilMartin, Marta
Renovanz, Mirjam
Touat, Mehdi
Wen, Patrick Y.
Wick, Antje
Chene, Laurent
Gouttefangeas, Cecile
Bonny, Christophe
Fagerberg, Jan
Wick, Wolfgang
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A672 - A672
[2] EO2401 PEPTIDE IMMUNOTHERAPY plus NIVOLUMAB plus /- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)
Reardon, David
Idbaih, Ahmed
Vieito, Maria
Ghiringhelli, Francois
Stradella, Agostina
Tabatabai, Ghazaleh
Burger, Michael C.
Mildenberger, Iris
Herrlinger, Ulrich
Wen, Patrick
Touat, Mehdi
Wick, Antje
Gonzalez, Macarena
Hervieu, Alice
GilMartin, Marta
Renovanz, Mirjam
Gouttefangeas, Cecile
Maia, Ana
Bonny, Christophe
Paillarse, Jean-Michel
Chene, Laurent
Fagerberg, Jan
Wick, Wolfgang
NEURO-ONCOLOGY, 2023, 25
[3] EO2401 (E) peptide immunotherapy plus nivolumab (N) plus /- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE
Wick, Wolfgang
Idbaih, Ahmed
Vieito, Maria
Ghiringhelli, Francois
Stradella, Agostina
Tabatabai, Ghazaleh
Burger, Michael C.
Mildenberger, Iris
Herrlinger, Ulrich
Wen, Patrick Y.
Touat, Mehdi
Wick, Antje
Gonzalez, Macarena
Hervieu, Alice
Gil-Martin, Marta
Renovanz, Mirjam
Maia, Ana
Bonny, Christophe
Fagerberg, Jan
Reardon, David A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 →